466 related articles for article (PubMed ID: 30937265)
1. Emerging Nano-/Microapproaches for Cancer Immunotherapy.
Mi Y; Hagan CT; Vincent BG; Wang AZ
Adv Sci (Weinh); 2019 Mar; 6(6):1801847. PubMed ID: 30937265
[TBL] [Abstract][Full Text] [Related]
2. Magnetic Nanostructures as Emerging Therapeutic Tools to Boost Anti-Tumour Immunity.
Persano S; Das P; Pellegrino T
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073106
[TBL] [Abstract][Full Text] [Related]
3. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
4. Lymph node-targeting nanovaccines for cancer immunotherapy.
Wang Q; Wang Z; Sun X; Jiang Q; Sun B; He Z; Zhang S; Luo C; Sun J
J Control Release; 2022 Nov; 351():102-122. PubMed ID: 36115556
[TBL] [Abstract][Full Text] [Related]
5. Overcoming T Cell Exhaustion in Tumor Microenvironment via Immune Checkpoint Modulation with Nano-Delivery Systems for Enhanced Immunotherapy.
Huang X; Zhang W
Small Methods; 2023 Dec; ():e2301326. PubMed ID: 38040834
[TBL] [Abstract][Full Text] [Related]
6. The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy.
Liu D; Badeti S; Dotti G; Jiang JG; Wang H; Dermody J; Soteropoulos P; Streck D; Birge RB; Liu C
Cell Commun Signal; 2020 Aug; 18(1):134. PubMed ID: 32843053
[TBL] [Abstract][Full Text] [Related]
7. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
8. Light-responsive nanomedicine for cancer immunotherapy.
Kang W; Liu Y; Wang W
Acta Pharm Sin B; 2023 Jun; 13(6):2346-2368. PubMed ID: 37425044
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
10. Local scaffold-assisted delivery of immunotherapeutic agents for improved cancer immunotherapy.
Shang Q; Dong Y; Su Y; Leslie F; Sun M; Wang F
Adv Drug Deliv Rev; 2022 Jun; 185():114308. PubMed ID: 35472398
[TBL] [Abstract][Full Text] [Related]
11. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
[TBL] [Abstract][Full Text] [Related]
12. Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy.
Huang P; Wang X; Liang X; Yang J; Zhang C; Kong D; Wang W
Acta Biomater; 2019 Feb; 85():1-26. PubMed ID: 30579043
[TBL] [Abstract][Full Text] [Related]
13. Bioengineering of nano metal-organic frameworks for cancer immunotherapy.
Chong G; Zang J; Han Y; Su R; Weeranoppanant N; Dong H; Li Y
Nano Res; 2021; 14(5):1244-1259. PubMed ID: 33250971
[TBL] [Abstract][Full Text] [Related]
14. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
[TBL] [Abstract][Full Text] [Related]
15. Advances in nano-immunotherapy for hematological malignancies.
Xu J; Liu W; Fan F; Zhang B; Sun C; Hu Y
Exp Hematol Oncol; 2024 May; 13(1):57. PubMed ID: 38796455
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
17. Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells.
Yong SB; Chung JY; Song Y; Kim J; Ra S; Kim YH
Biomaterials; 2019 Oct; 219():119401. PubMed ID: 31398571
[TBL] [Abstract][Full Text] [Related]
18. Tumor neoantigens: Novel strategies for application of cancer immunotherapy.
Guan H; Wu Y; Li LU; Yang Y; Qiu S; Zhao Z; Chu X; He J; Chen Z; Zhang Y; Ding H; Pan J; Pan Y
Oncol Res; 2023; 31(4):437-448. PubMed ID: 37415744
[TBL] [Abstract][Full Text] [Related]
19. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
20. The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities.
Sanaei MJ; Pourbagheri-Sigaroodi A; Kaveh V; Sheikholeslami SA; Salari S; Bashash D
Crit Rev Oncol Hematol; 2021 Jan; 157():103160. PubMed ID: 33220601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
